Physician profile
Danielle M Nelson
NPI 1013203769
$4,533.05
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $195 · 2021: $739 · 2022: $655 · 2023: $1,052 · 2024: $1,061 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.46 |
| Education | $205.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.17 | 2019-2025 | |
| Amgen INC. | $633.81 | 2020-2024 | Otezla |
| Galderma Laboratories, L.P. | $392.99 | 2019-2024 | Aklief |
| Regeneron Healthcare Solutions, INC. | $325.75 | 2019-2025 | Dupixent |
| Genzyme Corporation | $319.39 | 2020-2025 | |
| Lilly USA, LLC | $304.54 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $278.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $220.70 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $180.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $159.36 | 2023-2024 | Sotyktu |
| Incyte Corporation | $157.38 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $123.71 | 2019-2022 | |
| Janssen Biotech, INC. | $81.17 | 2019-2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Sun Pharmaceutical Industries INC. | $76.62 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $61.84 | 2019 | |
| Aclaris Therapeutics, INC. | $54.49 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.42 | 2019 | |
| Arcutis Biotherapeutics, INC. | $32.87 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $19.70 | 2024 | Vtama |
| Ucb, INC. | $19.13 | 2022 | |
| Almirall LLC | $19.05 | 2021 | |
| Dermira, INC. | $18.84 | 2021 | |
| Journey Medical Corporation | $17.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2023 | Spevigo |
| Epi Health, LLC | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.